In general, antidepressants function by increasing the availability of monoamines (serotonin, noradrenaline, and/or dopamine) in the synapse; these monoamines are thought to be depleted in depression.1
- SSRIs, SNRIs and TCAs achieve this by blocking one or more of the monoamine transporters, thus preventing the neurotransmitters from being taken back into the axon terminal that released them.1
- MAOIs achieve this by inhibiting the activity of the monoamine oxidase enzyme (acting as an ‘enzyme inhibitor’) and thus preventing the breakdown of neurotransmitters.1
MAOI=monoamine oxidase inhibitor; SSRI=selective serotonin reuptake inhibitor; SNRI=serotonin–noradrenaline reuptake inhibitor; TCA=tricyclic antidepressant.
Related content
Major Depressive Disorder (MDD) is a highly prevalent psychiatric condition with significant individual and socio-economic burden. Despite the broad availability of numerous effective therapeutic interventions, up to 30% of patients fail to achieve adequate symptom relief and are classified as having treatment-resistant depression (TRD). TRD represents a significant clinical challenge, affecting approximately 30% of individuals with MDD who fail to respond to at least two adequate antidepressant trials.
Sequential treatment optimization scheme for major depressive disorder generated according to international evidence.
Key steps for managing factors that may confound antidepressant treatment response, including dose, side effects, comorbidities, stressors, adherence, pharmacogenomics, interactions, and treatment algorithms.